Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterised by a stubbornly low 5-year survival which is essentially unchanged in the past 5 decades. Despite recent advances in chemotherapy and surgical outcomes, progress continues to lag behind that of other cancers. The PDAC microenvironment is characterised by a dense, fibrotic stroma of which cancer-associated fibroblasts (CAFs) are key players. CAFs and fibrosis were initially thought to be uniformly tumour-promoting, however this doctrine is now being challenged by a wealth of evidence demonstrating CAF phenotypic and functional heterogeneity. Recent technological advances have allowed for the molecular profiling of the PDAC tumour microenvironment at exceptional detail, and these technologies are being leveraged at pace to improve our understanding of this previously elusive cell population. In this review we discuss CAF heterogeneity and recent developments in CAF biology. We explore the complex relationship between CAFs and other cell types within the PDAC microenvironment. We discuss the potential for therapeutic targeting of CAFs, and we finally provide an overview of future directions for the field and the possibility of improving outcomes for patients with this devastating disease.

Automated summary

This article discusses the heterogeneity of cancer-associated fibroblasts (CAFs) and their role in the pancreatic ductal adenocarcinoma (PDAC) microenvironment. Molecular profiling allows for a better understanding of the characteristics of CAFs in the PDAC tumor microenvironment. The article also explores the complex relationship between CAFs and other cell types within the PDAC microenvironment, as well as the potential for therapeutic targeting of CAFs.